European Primary Care Cardiovascular Society

Lipid lowering: the evidence, the guidelines, the clinical reality

EPCCS CV Summit 2018

Mar. 16, 2018 - EPCCS 2018, Barcelona, Spain - Professor Frank Visseren, Utrecht, The Netherlands
A recording of the lecture by Prof. Visseren, on practical issues of managing elevated lipids and statins: why do many patients not take their medication, and how can we improve this?

EPCCS 2018 A recording of the lecture by Prof. Visseren, on practical issues of managing elevated lipids and statins: why do many patients not take their medication, and how can we improve this?

Google searches and statin-intolerance

May 16, 2018 - news

A Google-driven nocebo effect may underlie statin intolerance, as countries with many websites on statin side-effects showed a higher prevalence of statin intolerance.

CV benefit of long-term statin treatment far outweighs adverse effects, says EAS Consensus Panel

May 3, 2018 - Mach F et al., Eur Atheroscl Soc Consensus Panel - Eur Heart J, 2018

Based on objective and critical appraisal of the literature on potential adverse effects of statins, the EAS Consensus Panel concludes that statin treatment is remarkably safe.

Conventional lipid-lowering therapy does not get heFH patients to recommended LDL-c targets

May 1, 2018 - Hartgers ML et al., - J Clin Lipidol. 2018

A model assuming 100% adherence to maximal statin dose showed that only 10% of heFH patients with CHD would reach guideline-recommended LDL-c goal, and about half of those without CHD.

Variation in time to benefit among clinical trials of lipid-lowering therapies

Apr. 30, 2018 - Barter PJ, and Waters DD. - J Clin Lipidol 2018

Early benefit should not be expected with all lipid-lowering drugs, and the lack of outcome curve separation up to 30 months does not preclude eventual benefit.

Statins are underutilized in peripheral artery disease patients

Apr. 10, 2018 - Arya S et al. - Circulation. 2018

In a large community-based database, in patients with peripheral artery disease, statin therapy was associated with a significant reduction of amputations and mortality compared with no statin use.

Slides | Lipid-lowering: the evidence, the guidelines, the clinical reality

Mar. 15, 2018 - Barcelona, Spain - Prof. Frank Visseren - Utrecht, The Netherlands
**EPCCS 2018** Slides prepared and presented byProf. Frank Visseren (Utrecht, The Netherlands), here offered as an educational service.

EPCCS 2018 Slides prepared and presented byProf. Frank Visseren (Utrecht, The Netherlands), here offered as an educational service.

Managing elevated lipids and statins – the good, the bad and the ugly?

Prof. Frank Visseren - UMC Utrecht, The Netherlands

EPCCS 2018 An impression of the presentation of Prof. Frank Visseren on the evidence, the guidelines and the clinical reality of lipid-lowering therapies, given during the Annual EPCCS CV Summit.

Treatment of high-risk ACS patients may change based on ODYSSEY OUTCOMES study results

Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA
Dr. Valentin Fuster explains why he thinks that the ODYSSEY OUTCOMES results with the PCSK9 inhibitor alirocumab can change clinical practice. In the results he also sees the message that LDL levels now considered normal, may actually be too high.

ACC 2018 Dr. Valentin Fuster explains why he thinks that the results with the PCSK9 inhibitor alirocumab can change clinical practice. In the results he also sees the message that LDL levels now considered normal, may actually be too high.

PCSK9 inhibitor has very good benefit-to-risk profile in high risk ACS patients in ODYSSEY OUTCOMES trial

Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Prof. Gabriel Steg - Paris, France
Prof. Gabriel Steg discusses the 15% reduction of MACE obtained with alirocumab, with a good safety profile. The observed CV benefit was greater in patients who had a higher LDL-c at baseline.

ACC 2018 Prof. Gabriel Steg discusses the 15% reduction of MACE obtained with alirocumab, with a good safety profile. The observed CV benefit was greater in patients who had a higher LDL-c at baseline.

Shift of statin eligibility to more subjects at intermediate CV risk with new criteria

Mar. 21, 2018 - Cesena FHY, et al. - Am J Cardiol 2018

Defining statin eligibility based on the predicted CV benefit, rather than the absolute CV risk, shifts statin eligibility to more intermediate CV risk subjects.

MACE safely reduced by another PCSK9 inhibitor in long term outcomes trial in high-risk patients

Presented at ACC.18 by Ph. Gabriel Steg (Paris, France)

Mar. 13, 2018 - news

ACC 2018 Treatment with alirocumab on top of high-intensity statins lowered MACE by 15% in patients with recent ACS in the ODYSSEY OUTCOMES trial and was associated with a lower rate of all-cause death.